Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
about
Neurodegeneration in multiple sclerosis: novel treatment strategiesIntravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatmEvidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process[Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis].The magnetic resonance imaging 'rule of five': predicting the occurrence of relapse.Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic reviewInterferon-beta1b for multiple sclerosis.Treatment of children and adolescents with multiple sclerosis.Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.New developments in understanding and treating neuroinflammation.Longitudinal predictors of attitudes toward aging among women with multiple sclerosis.How to diagnose multiple sclerosis and what are the pitfalls.Therapies for multiple sclerosis: considerations in the pediatric patient.New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis.Aging with multiple sclerosis: cognitive, emotional and neuropathological considerations.Remyelinating strategies in multiple sclerosis.Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs.The indirect costs of multiple sclerosis: systematic review and meta-analysis.Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.Can abnormal evoked potentials predict future clinical disability in patients with multiple sclerosis?Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis.Pain acts through fatigue to affect participation in individuals with multiple sclerosis.Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendationsAn open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.Contribution of symptom clusters to multiple sclerosis consequences.Effects of different exercise modalities on ataxia in multiple sclerosis patients: a randomized controlled study.Multiple sclerosis attacks are associated with picornavirus infections.Epitope mapping of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a mouse model of multiple sclerosis: microwave-assisted synthesis of the peptide antigens and ELISA screening.Telemedicine for multiple sclerosis patients: assessment using Health Value Compass.Maintaining quality of life in multiple sclerosis: fact, fiction, or limited reality?Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b
P2860
Q22241472-BFF15FAF-56E8-497F-BA44-D3465A764880Q28255051-595AE3A3-CEAE-4634-A67D-50F98EE4CFC8Q29542960-D1348B33-D8CD-4888-82B2-6B966690A6AAQ31149165-46B5A335-15CF-45A7-A5BC-969E3DBA03C8Q34026205-5BB41127-14A3-4D93-9423-7E3C662A7CDEQ34684373-42233C58-41F6-49FB-B181-50810ECD7E81Q36106790-12191F62-864B-4176-930F-D84624BBAD29Q36153390-CFE6ECC8-1298-470C-B00E-A1E3DBF2B8C4Q36699401-AB3D2DDD-226A-4940-8402-DAB5852E3BDDQ37057309-FB537DE1-5BC1-472B-9AD1-C9A11A14D4F1Q37391133-8AF9BEB2-5E7A-47E2-A092-80FCCBBCCE0FQ37612000-7436EB2C-F287-4481-90F8-0BB2B05FD9EAQ37827690-866BA9E4-2DC7-41DF-AD72-0DA4BCD63510Q38103283-D252B605-7A01-443A-80BD-0DB681EF59C2Q38212039-E33CB941-F879-42FE-BEEC-A5DE833130F9Q38261543-0D8E45F3-667E-458A-85E2-CDA62F4D0A78Q38315992-5DB600F4-A12C-468C-A3F5-CD14A3C96509Q38550252-E21DF059-FA4A-4578-B354-24CE5E232F3EQ40148514-6BC7B86A-37B9-4D14-8499-C13EEFBBEA69Q40294325-3D73D25A-81EB-4C34-B780-7EA0F6F9DE0EQ40352907-B218CBF4-FE42-4813-ACEC-EA6EBB2B4C6FQ41502038-1F837B11-9CD1-4567-A06B-93A8D629A427Q41712035-3275BD44-1B38-446B-99F4-72767A8FECD2Q42637668-AE3BC571-F258-4D7C-8661-4CDD8F5553ECQ47813773-D258B23C-64DB-4C8E-BD8D-8A01AFFF7B22Q47962602-7C720A8E-9A44-44B1-ABFB-046D2806F259Q47986078-5434DB19-7833-4481-AB9B-70DEA4440547Q48089426-6865AC2A-8B66-44B0-B5DF-BA6C31854825Q48578968-DAA107CA-C167-4AE7-975C-F77ACBB4AD70Q48771045-3723388F-C523-492D-9287-BFDEB195FE0DQ57085803-EEE5A0C8-6DAC-44E4-A6C9-5544BD7846BE
P2860
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
@ast
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
@en
type
label
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
@ast
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
@en
prefLabel
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
@ast
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
@en
P1433
P1476
Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
@en
P2093
Canadian Multiple Sclerosis Working Group
Paul O'Connor
P356
10.1212/WNL.59.6_SUPPL_3.S1
P407
P433
P577
2002-09-01T00:00:00Z